Study on Nivolumab and Ipilimumab for Treating Advanced Rare Genitourinary Tumors

Inclusion Criteria

• Must be 18 years or older.
• Have a performance status that allows for daily activities with some restrictions.
• Have advanced or metastatic rare genitourinary cancers, such as certain bladder cancers or neuroendocrine tumors.
• Only certain groups, like those with bladder cancer, are currently open for new participants.
• Must provide a tumor sample for testing, if available, and be willing to have a biopsy if needed.
• Have measurable disease based on specific criteria.
• Have adequate organ function as shown by blood tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control.
• Must be able to understand and agree to follow the study procedures.

Exclusion Criteria

• Have previously used similar immune checkpoint inhibitors for these cancers.
• Are taking certain immunosuppressive medications.
• Have had recent chemotherapy, hormone therapy, or other investigational treatments.
• Have untreated or active brain metastases.
• Have other cancers within the last 5 years, except for certain low-risk types.
• Have severe allergies to the study drugs.
• Have active autoimmune diseases requiring treatment.
• Have uncontrolled adrenal insufficiency.
• Have certain lung diseases or active infections like HIV or hepatitis.
• Have significant heart disease or uncontrolled high blood pressure.
• Have had recent major surgery or other serious medical conditions that could interfere with the study.